Skip to main content
Guerbet logo

Guerbet — Investor Relations & Filings

Ticker · GBT ISIN · FR0000032526 LEI · 969500WV1U1WQ059L135 PA Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2010-04-09 Declaration of Voting R…
Country FR France
Listing PA GBT

About Guerbet

https://www.guerbet.com

Guerbet is a global specialist in medical imaging, offering a comprehensive range of solutions and services for diagnostic and interventional procedures. The company develops and manufactures contrast media, medical devices such as injectors, and related software for X-ray, Magnetic Resonance Imaging (MRI), and Interventional Imaging. With a history of innovation dating back to 1926, Guerbet focuses on providing healthcare professionals with tools to enhance diagnostic accuracy and improve patient care. Its portfolio is designed to support a wide array of clinical applications, from initial diagnosis to treatment monitoring.

Recent filings

Filing Released Lang Actions
Déclaration relative au nombre d'actions et de droits de vote au 31 Mars 2010
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE" (Declaration relative to the number of voting rights and shares comprising the capital of the company). It explicitly references compliance with French commercial code (L. 233-8 II) and AMF regulations (article 222-12-5) for monthly publication of total voting rights and share capital changes. The content is a table detailing the number of shares, treasury shares, and total/exercisable voting rights as of March 31, 2010. This specific type of mandatory disclosure regarding the total number of voting rights is best classified as a general regulatory filing or announcement, as it does not fit the specific definitions for AGM materials, Director's Dealing, or Capital Changes, but rather reports on the structure of voting rights. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for mandatory, periodic regulatory disclosures that don't fit a more specific financial report type. However, since the content is a direct declaration of voting rights structure, it strongly aligns with the concept of a voting rights announcement, which is often grouped under general regulatory filings if a more specific code isn't available. Reviewing the definitions, 'DVA' (Declaration of Voting Results & Voting Rights Announcements) is the closest match, as this document declares the current state of voting rights, even if it's not the *result* of a specific vote.
2010-04-09 French
Des résultats marqués par une forte croissance en volume dans un contexte compétitif
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and presents summarized consolidated financial figures for the year 2009 compared to 2008, including revenue, R&D expenses, operating income, and net income. It discusses business performance, product growth (Dotarem, Xenetix), and future strategy (Cap 2016). This format, providing key financial highlights immediately following the period end, is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), nor is it a transcript (CT) or a formal audit report (AR). The document is short and serves as the initial announcement of results. FY 2009
2010-03-02 French
Results buoyed by growth in volume in a competitive environment
Earnings Release Classification · 98% confidence The document is explicitly titled 'PRESS RELEASE' and presents key consolidated financial data for the year 2009 compared to 2008, including Net sales, operating income, and net income. It discusses revenue trends, R&D, and results. This format, focusing on the immediate release of period-end financial highlights, strongly indicates an Earnings Release (ER). Although it mentions a dividend proposal for the upcoming General Meeting, the primary content is the financial performance summary for the preceding year. It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial announcement of results. FY 2009
2010-03-02 English
Déclaration relative au nombre d'actions et de droits de vote au 28 Février 2010
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE" (Declaration relative to the number of voting rights and shares comprising the capital of the company). It explicitly references French regulatory articles (Code de commerce, AMF general regulation) and provides a table detailing the total number of shares, treasury shares, and total voting rights as of February 28, 2010. This content directly corresponds to the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which covers official announcements regarding the total number of voting rights and shares.
2010-03-01 French
Chiffre d'Affaires du quatrième trimestre 2009
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and focuses on the "Chiffre d'affaires 2009" (2009 Revenue). It presents summarized, high-level quarterly and annual revenue figures (tables showing 2009 vs 2008 performance) and brief commentary on product performance (Dotarem, Xenetix). This structure, focusing on key financial highlights released before the full report, strongly indicates an Earnings Release (ER). Furthermore, the text explicitly states that the complete results will be made public on March 2, 2010, confirming this document is the preliminary announcement. The document length (3110 chars) is short, consistent with a press release rather than a comprehensive report like a 10-K or IR. FY 2009
2010-02-11 French
Guerbet 2009 Net Sales
Earnings Release Classification · 98% confidence The document is titled "PRESS RELEASE" and provides summarized consolidated group revenue figures for the full year 2009, broken down by quarter and region, comparing them to 2008. It highlights key product performance (Dotarem, Xenetix) and provides a brief outlook on operating income and capital spending. This structure, focusing on key financial highlights for a period (the full year 2009), strongly indicates an Earnings Release (ER). Furthermore, the document explicitly states that a 'complete presentation of Group results for fiscal 2009 with comments will be published on 2 March 2010,' confirming this document is the initial, high-level announcement, not the comprehensive report itself. The document length (2704 chars) is short, supporting the classification as a release rather than a full report. FY 2009
2010-02-11 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.